FEC Mobilized Stem Cells for High-dose Therapy in Breast Cancer Patients

Authors

  • Henrik Lindman Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)
  • Tom Wiklund Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)
  • Harald Holte Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)
  • Per Ljungman Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)
  • Carl Blomqvist Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)
  • Gunnar Kvalheim Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)
  • Mats Bengtsson Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)
  • Martin Höglund Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)
  • Nils Wilking Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)
  • Jonas Bergh Department of Oncology, University Hospital, Uppsala, Sweden (H. Lindman, J. Bergh), Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland (T. Wiklund, C. Blomqvist), Department of Medicine, Norwegian Radium Hospital, Oslo, Norway (H. Holte, G. Kvalheim), Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P. Ljungman), Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden (M. Bengtsson), Department of Medicine, University Hospital, Uppsala, Sweden (M. Ho glund), Radiumhemmet, Karolinska Hospital, Stockholm, Sweden (N. Wilking)

DOI:

https://doi.org/10.1080/028418699431672

Abstract

The feasibility of mobilizing peripheral blood stem cells (PBSC) using anthracycline containing polychemotherapy and G-CSF on the first 50 patients randomized to the high-dose arm in the adjuvant SBG 9401 is investigated. The patients were treated with standard FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2) for two courses followed by a modified third FEC course with a C dose of 1200 mg/m2 supported with subcutaneous G-CSF (filgrastim) at 5 mg/kg followed by harvest around day 11. The mean yield of CD34+

Downloads

Download data is not yet available.

Downloads

Published

1999-01-01

How to Cite

Lindman, H., Wiklund, T., Holte, H., Ljungman, P., Blomqvist, C., Kvalheim, G., … Bergh, J. (1999). FEC Mobilized Stem Cells for High-dose Therapy in Breast Cancer Patients. Acta Oncologica, 38(2), 239–245. https://doi.org/10.1080/028418699431672

Issue

Vol. 38 No. 2 (1999): Acta Oncologica

Section

Articles